1. Home
  2. ITOS vs MACI Comparison

ITOS vs MACI Comparison

Compare ITOS & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • MACI
  • Stock Information
  • Founded
  • ITOS 2011
  • MACI 2024
  • Country
  • ITOS United States
  • MACI United States
  • Employees
  • ITOS N/A
  • MACI N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • MACI
  • Sector
  • ITOS Health Care
  • MACI
  • Exchange
  • ITOS Nasdaq
  • MACI NYSE
  • Market Cap
  • ITOS 270.7M
  • MACI 221.6M
  • IPO Year
  • ITOS 2020
  • MACI 2024
  • Fundamental
  • Price
  • ITOS $10.02
  • MACI $10.37
  • Analyst Decision
  • ITOS Hold
  • MACI
  • Analyst Count
  • ITOS 6
  • MACI 0
  • Target Price
  • ITOS $10.60
  • MACI N/A
  • AVG Volume (30 Days)
  • ITOS 2.6M
  • MACI 9.4K
  • Earning Date
  • ITOS 04-28-2025
  • MACI 01-01-0001
  • Dividend Yield
  • ITOS N/A
  • MACI N/A
  • EPS Growth
  • ITOS N/A
  • MACI N/A
  • EPS
  • ITOS N/A
  • MACI 0.33
  • Revenue
  • ITOS $35,000,000.00
  • MACI N/A
  • Revenue This Year
  • ITOS N/A
  • MACI N/A
  • Revenue Next Year
  • ITOS $31.74
  • MACI N/A
  • P/E Ratio
  • ITOS N/A
  • MACI $31.51
  • Revenue Growth
  • ITOS 177.89
  • MACI N/A
  • 52 Week Low
  • ITOS $4.80
  • MACI $9.95
  • 52 Week High
  • ITOS $18.13
  • MACI $10.40
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 73.75
  • MACI N/A
  • Support Level
  • ITOS $8.30
  • MACI N/A
  • Resistance Level
  • ITOS $11.35
  • MACI N/A
  • Average True Range (ATR)
  • ITOS 0.53
  • MACI 0.00
  • MACD
  • ITOS 0.22
  • MACI 0.00
  • Stochastic Oscillator
  • ITOS 71.15
  • MACI 0.00

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About MACI MELAR ACQUISITION CORP. I

Melar Acquisition Corp I is a blank check company.

Share on Social Networks: